Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
Key Points
Key Points
Patients with cancer are significantly more likely to develop VTE than people without cancer and experience higher rates of VTE recurrence and bleeding complications during VTE treatment.
Comprehensive management of VTE in patients with cancer includes both the identification of patients who are most likely to benefit from pharmacologic prophylaxis, as well as effective treatment to reduce the risk of VTE recurrence and mortality.
The current update adds apixaban as an option for the treatment of VTE in patients with cancer, and addresses recent evidence regarding direct factor Xa inhibitors for extended postoperative thromboprophylaxis.
Treatment
...Treatment...
...ospitalized patients who have acti...
...ed patients who have active malignancy...
...pharmacologic thromboprophylaxis shoul...
...ologic thromboprophylaxis should not be off...
...atients with cancer (Khorana score [Table 2] ≥2...
...ts with multiple myeloma receiving...
...l patients with malignant disease undergoing m...
...UFH or LMWH should be commenced preoper...
...ical methods may be added to pharmacologic th...
...mbined regimen of pharmacologic and mec...
...rmacologic thromboprophylaxis for patients under...
...harmacologic thromboprophylaxis for up to 4 we...
...) Patients who are candidates for extended p...
...rnatively, patients may be offered prop...
...tial anticoagulation may involve LMWH, UFH, fon...
...dated) For long-term anticoagulation, L...
...lation with LMWH, direct factor Xa...
...ert opinion in the absence of randomized t...
...rtion of a vena cava filter may be of...
...patients with primary or metastatic central nerv...
...ntal PE and deep vein thrombosis should be treated...
...isolated subsegmental PE or splanchnic or visce...
...agulant use is not recommended to improve...
...is substantial variation in risk of...
...logists and members of the oncology team should e...
...ding off-label use in guideline recomm...
.... Predictive Model for Chemotherapy-asso...